Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Regular Articles

Inhibition of Microtubules and Cell Cycle Arrest by a New 1-Deaza-7,8-dihydropteridine Antitumor Drug, CI 980, and by Its Chiral Isomer, NSC 613863

Concepcion de Ines, Daniel Leynadier, Isabel Barasoain, Vincent Peyrot, Patrick Garcia, Claudette Briand, Gregory A. Rener and Carroll Temple Jr.
Concepcion de Ines
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Leynadier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel Barasoain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Peyrot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Garcia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudette Briand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory A. Rener
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carroll Temple Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 1994
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

CI 980 (NSC 613862; [S-(−)]) and NSC 613863 [R-(+)] are the two chiral isomers of ethyl 5-amino l,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-ylcarbamate (NSC 370147), which is a mitotic inhibitor with in vivo and in vitro activity against murine multidrug-resistant sublines. We have characterized the inhibition of in vitro microtubule assembly by the S (CI 980) and R (NSC 613863) enantiomers, their actions on the cytoplasmic microtubule network of epithelial-like PtK2 cells, and on the cell cycle of different human and murine leukemias and PtK2 cells. Assembly of purified tubulin, or tubulin plus microtubule-associated proteins, into microtubules was substoichiometrically inhibited by both compounds, which also induced a slow depolymerization of preassembled microtubules. Half inhibitory concentrations were 0.4–0.7 µm and 1.6–2.1 µm for the S and R isomers, respectively. Excess of both drugs induced polymerization of liganded tubulin into abnormal polymers similar to colchicine. The cytoplasmic microtubules of PtK2 cells were disrupted by both compounds in a concentration- and time-dependent manner, which was observed by indirect immunofluorescence microscopy and quantified by an enzyme-linked immunoassay of cytoskeletal tubulin. Half inhibitory concentrations were 6 nm S isomer, 100 nm R isomer, and 1 µm colchicine. Twenty nm S isomer or 500–700 nm R isomer gave nearly maximal effect. At these concentrations, half maximal microtubule depolymerization took place after 2 h of treatment. After drug removal, slow microtubule assembly and nearly complete reorganization of the cytoplasmic microtubules of PtK2 cells were observed (24 h). One nm S enantiomer or 25 nm R enantiomer induced mitotic arrest in 8 h in U937, HL60, and EL4 leukemias. PtK2 cells also stopped in mitosis after a 24-h incubation with 50 nm R isomer or S nm S isomer. The inhibition of cell division was irreversible in the leukemic cells, while PtK2 cells partially resumed growth. Although the interactions of CI 980 with microtubules in vitro are not very different from other drugs, it is a most potent cellular microtubule and mitotic inhibitor.

Footnotes

  • ↵1 This work was supported by Grant PB 87-0230 from the Direccion General de Investigacion Cientifica y Tecnica, French-Spanish grants, and grants from Association pour la Recherche sur le Cancer Federation de Centres de lutte Contre Cancer.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Received July 16, 1993.
  • Accepted October 29, 1993.
  • ©1994 American Association for Cancer Research.
PreviousNext
Back to top
January 1994
Volume 54, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of Microtubules and Cell Cycle Arrest by a New 1-Deaza-7,8-dihydropteridine Antitumor Drug, CI 980, and by Its Chiral Isomer, NSC 613863
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Inhibition of Microtubules and Cell Cycle Arrest by a New 1-Deaza-7,8-dihydropteridine Antitumor Drug, CI 980, and by Its Chiral Isomer, NSC 613863
Concepcion de Ines, Daniel Leynadier, Isabel Barasoain, Vincent Peyrot, Patrick Garcia, Claudette Briand, Gregory A. Rener and Carroll Temple Jr.
Cancer Res January 1 1994 (54) (1) 75-84;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Inhibition of Microtubules and Cell Cycle Arrest by a New 1-Deaza-7,8-dihydropteridine Antitumor Drug, CI 980, and by Its Chiral Isomer, NSC 613863
Concepcion de Ines, Daniel Leynadier, Isabel Barasoain, Vincent Peyrot, Patrick Garcia, Claudette Briand, Gregory A. Rener and Carroll Temple Jr.
Cancer Res January 1 1994 (54) (1) 75-84;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Regular Articles

  • Diosmin and Diosmetin Are Agonists of the Aryl Hydrocarbon Receptor That Differentially Affect Cytochrome P450 1A1 Activity
  • IFN-γ Induces Cell Growth Inhibition by Fas-mediated Apoptosis: Requirement of STAT1 Protein for Up-Regulation of Fas and FasL Expression
  • Detection and Quantitation of Circulating Cancer Cells in the Peripheral Blood of Lung Cancer Patients
Show more Regular Articles

Biochemistry and Biophysics

  • Decreased Repair Activities of 1,N6-Ethenoadenine and 3,N4-Ethenocytosine in Lung Adenocarcinoma Patients
  • Identification and Characterization of Signal Transducer and Activator of Transcription 3 Recruitment Sites within the Epidermal Growth Factor Receptor
  • A Novel Telomerase Template Antagonist (GRN163) as a Potential Anticancer Agent
Show more Biochemistry and Biophysics

Articles

  • Decreased Repair Activities of 1,N6-Ethenoadenine and 3,N4-Ethenocytosine in Lung Adenocarcinoma Patients
  • Identification and Characterization of Signal Transducer and Activator of Transcription 3 Recruitment Sites within the Epidermal Growth Factor Receptor
  • A Novel Telomerase Template Antagonist (GRN163) as a Potential Anticancer Agent
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement